Some drugmakers are expanding production in Africa to take advantage of a growing number of countries where rising incomes and national healthcare can pay for new meds. Now, through a number of sources of financing, a new plant will be built to manufacture yellow fever vaccine, a protection that has been in short supply.
India's Strides Shasun has been expanding and will add a seventh manufacturing site to its operations in Africa after buying controlling interest in a Kenyan drug producer.
Valeant's Bausch + Lomb has voluntarily initiated a massive recall of an eye dilation med after learning that more than 1 million bottles may have been shipped with the wrong medication insert.
Sanofi says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency.
India's Ipca Laboratories is facing FDA regulatory actions at plants in India, but the drugmaker's small-scale API and CRO operation in the U.K. intends to again increase capacity, this time by about 30%.
Ever wonder where the websites selling unapproved and sometimes counterfeit drugs get those products? According to the Department of Justice, many of them came from a Pakistani man and his company, JNS Impex.
Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.
Piramal Enterprises, with a big dose of incentives, snapped up Coldstream Laboratories last year from the University of Kentucky to get its expertise in sterile injectable meds. Now it has plans on investing another sizable chunk to expand the CDMO.
Sun Pharmaceutical, which has had its U.S. sales gut-kicked as its deal with FDA concerns at some of its manufacturing plants, has launched in the U.S. its copy of Novartis' blockbuster blood cancer drug Gleevec. With its first-to-file approval, the Sun generic will have the market to itself for 6 months.
India's Aurobindo Pharma, in the midst of expanding its manufacturing targeted at the U.S., has gotten a production unit signed off on by the FDA. A second one, however, came up short of the finish line.
It has been another tough week for some of India's troubled drugmakers. Wockhardt, which has two plants banned by the FDA, saw its hopes stymied for getting export approval for a different facility that it had hoped could help it recoup some of its lost U.S. revenues. And India's Ipca Laboratories, which has three plants on the import alert list, said Monday it has now gotten a warning letter for the facilities.
Years ago, German CDMO Vetter determined that in addition to building out its manufacturing capacity, it needed to expand its IT infrastructure to continue to satisfy clients. Now after two years, Vetter has wrapped up work on a 91,500-square-foot multipurpose facility in Schuetzenstrasse, Germany, that bulks up computing operations.
Teva Pharmaceuticals' efforts to cut costs by making its manufacturing more efficient have landed at a plant in the U.K. where the generics leader will cut dozens of jobs but add some new positions with more specialized skills.
Allergan is putting finishing touches on a $50 million expansion of its flagship plant in Waco, TX, but CEO Brent Saunders says the drugmaker may be looking to the facility for more capacity and add jobs as result.
Since Eli Lilly closed its $5.4 billion deal last year to buy Novartis Animal Health, Lilly has been doing an in-depth evaluation of its global manufacturing operations. The conclusions it has reached are bad news for more than 100 workers at plants in Ireland and Scotland.
Generic drug producer Mylan has had some manufacturing issues of late that have resulted in recalls of cancer drugs made for Pfizer. Now it finds itself in the reverse situation. Mayne Pharma is recalling more than 74,000 bottles of a topical pain drug used in cataract surgeries that it manufactured but which is licensed to and sold by Mylan.
GlaxoSmithKline says "unexpected global demand" for its meningitis B vaccine Bexsero has resulted in "supply constraints," which in turn has led to a shortage for private clinics in the U.K.
Novartis has rid itself of more than two dozen manufacturing sites in the past few years, closing or selling some facilities and handing off a bunch to GlaxoSmithKline as part of their big asset swap. Now the Swiss drugmaker says it intends to organize what is left into one overreaching operation in expectation of saving some serious money by 2020.
Baxter International had to recall two lots of saline solution earlier this month after customers discovered insects in some containers. Now the drugmaker is recalling more saline, as well as another replenishment product and an antibiotic, after customers complained of particulate matter that turned out to be cardboard, cloth and dried skin.
With cash in hand and an official nod from India, Sweden's Recipharm is just about ready to close on its deal to buy a majority stake in Indian sterile injectables maker Nitin Lifesciences.